Growth hormone secretagogues (GHS) represent a class of research compounds that stimulate growth hormone release through mechanisms distinct from exogenous GH administration. Three compounds — CJC-1295, Ipamorelin, and Sermorelin — have generated substantial published literature and are among the most widely used peptides in GH-axis research models.
Understanding the GH Secretagogue Mechanism
GH secretagogues work through two primary receptor pathways: the growth hormone-releasing hormone receptor (GHRHR) and the ghrelin/GH secretagogue receptor (GHSR). Understanding which receptor pathway a compound targets is fundamental to designing research protocols and interpreting results.
- GHRHR agonists (CJC-1295, Sermorelin): Mimic the action of endogenous GHRH, stimulating the pituitary to release GH in a pattern that approximates natural pulsatile release.
- GHSR agonists / GHRPs (Ipamorelin): Activate the ghrelin receptor, providing a complementary but mechanistically distinct GH release stimulus.
CJC-1295: Extended Half-Life GHRH Analogue
CJC-1295 is a synthetic analogue of growth hormone-releasing hormone (GHRH) with an extended half-life compared to native GHRH (which has a plasma half-life of under 7 minutes). The extended-release version — CJC-1295 with DAC (Drug Affinity Complex) — achieves this through a maleimidoproprionic acid (MPA) modification that enables covalent binding to plasma albumin, dramatically extending the active period in research models.
CJC-1295 without DAC (also called Modified GRF 1-29 or Mod GRF 1-29) provides a shorter active window and is often combined with a GHRP compound in pulsatile dosing protocols in animal research models.
Key Research Parameters for CJC-1295
- Receptor target: GHRHR
- Without DAC half-life: ~30 minutes in rodent models
- With DAC half-life: 6–8 days in primate models (published data)
- GH pulse pattern: Maintains normal pulsatile pattern (unlike continuous GH)
Ipamorelin: Selective GHRP with Minimal Off-Target Effects
Ipamorelin is a pentapeptide GH secretagogue that acts as a selective agonist of the GHSR (ghrelin receptor). Published research has highlighted its selectivity profile compared to earlier generation GHRPs such as GHRP-6 — Ipamorelin demonstrates minimal effect on cortisol and ACTH release at research doses, making it a cleaner model compound for GH-specific axis studies.
The CJC-1295 + Ipamorelin combination has become a standard research model precisely because the two compounds act on different receptors, providing synergistic GH stimulation through complementary pathways. The combination allows researchers to study the interplay between GHRHR and GHSR signalling simultaneously.
Sermorelin: The Native-Sequence Reference Compound
Sermorelin (GHRH 1-29) is the biologically active fragment of endogenous growth hormone-releasing hormone. As the first 29 amino acids of native GHRH, it provides researchers with a reference compound that closely mirrors the physiological stimulus, making it valuable as a baseline control in comparative GH secretagogue studies.
Its shorter half-life relative to CJC-1295 analogues actually makes it useful in research designs where tight temporal control over GH pulse timing is required. Multiple published studies have used Sermorelin as the reference arm against which novel GHRH analogues are compared.
Combination Research Protocols
A key insight from the GH secretagogue literature is that GHRHR agonists and GHSR agonists produce synergistic effects when co-administered in animal models. This has made pre-blended peptide vials — such as CJC-1295 + Ipamorelin or Sermorelin + Ipamorelin blends — a practical format for researchers studying combined GH axis modulation.
EdgeChems provides pre-blended lyophilized vials of the most common research combinations: CJC-1295 (no DAC) + Ipamorelin, CJC-1295 (with DAC) for extended-release models, and Sermorelin + Ipamorelin. All are tested to ≥99% purity with batch-specific Certificates of Analysis.
Purity and Formulation Considerations
For GH secretagogue research, lyophilization is strongly preferred over liquid formulations. Peptide bonds in GHRH analogues are susceptible to hydrolysis, and lyophilized powder has dramatically better shelf stability. At EdgeChems, all GH secretagogue vials are lyophilized, individually nitrogen-flushed, and shipped with cold-chain packaging to maintain integrity during transit.
Independent HPLC testing confirms ≥99% purity for each batch. Mass spectrometry sequence verification is available on the Certificate of Analysis for each compound.
All EdgeChems research compounds are for laboratory and in-vitro research purposes only. Not for human or veterinary use. Not for resale.